Back to Top
Charles H. Hood Foundation | Plakous Therapeutics
By identifying innovative pediatric advancements and providing funding in the critical phases of development, we are able to expedite high-impact breakthroughs that improve the health and lives of millions.
portfolio_page-template-default,single,single-portfolio_page,postid-18621,ajax_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-1.0.0,qode-theme-ver-10.0,wpb-js-composer js-comp-ver-4.12,vc_responsive

Program Related Investment

Plakous Therapeutics

Necrotizing Enterocolitis (NEC) is the leading cause of death in babies of very low birth weight. Current treatments are inadequate, and new therapies are difficult to introduce to this population. Plakous Therapeutics is developing a novel therapeutic to prevent neonatal diseases and heal diseases of inflammation, starting with NEC. Learn more.